Denosumab biosimilar (Boan Biopharma/Luye)

地舒单抗生物类似药（博安生物/绿叶制药）

Report date: 2025/12/10 14:49:37

Base Information

Drug NameDenosumab biosimilar (Boan Biopharma/Luye)
Drug Alias NameRecombinant whole human anti-RANKL monoclonal antibody (Boan Biopharma/luye Pharma)重组抗RANKL全人单克隆抗体（博安生物/绿叶制药）Denosumab biosimilar (Boan Biopharma/Luye)Denosumab生物类似药（博安生物/绿叶制药）Xgeva生物类似药（博安生物/绿叶制药） +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[8] 
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryMainland China
Original Approved Date2022/11/08
Country/TerritoryCzechiaBulgariaUnited States +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Boan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQingdao Guoxin Pharmaceutical Co LtdLuye Pharma Group LtdShandong Kexing Bio-Products Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[6] 
Inactive IndicationsOsteoporosisNeoplasms

Other Information

ATC CodeM05BX04
Related LinksN/A